公开(公告)号：EP2580596B1

公开(公告)日：2015-02-25

申请号：EP11726110.7

申请日：2011-06-10

申请人： metanomics Health GmbH ,  Universitätsklinikum Schleswig-Holstein

发明人： KAMP, Hennicke ,  RENNEFAHRT, Ulrike ,  FUHRMANN, Jens ,  REIN, Dietrich ,  HAMPE, Jochen ,  SCHAFMEYER, Clemens

IPC分类号： G01N33/68 ,  G01N33/50 ,  G01N33/92 ,  G06F19/00

CPC分类号： G01N33/50 ,  G01N33/6812 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/085 ,  Y02A90/26

摘要： The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a liver disease in a subject and a method of differentiating between NASH and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

公开(公告)号：EP2580596A1

公开(公告)日：2013-04-17

申请号：EP11726110.7

申请日：2011-06-10

申请人： metanomics Health GmbH ,  Universitätsklinikum Schleswig-Holstein

发明人： KAMP, Hennicke ,  RENNEFAHRT, Ulrike ,  FUHRMANN, Jens ,  REIN, Dietrich ,  HAMPE, Jochen ,  SCHAFMEYER, Clemens

IPC分类号： G01N33/68 ,  G06F19/00

CPC分类号： G01N33/50 ,  G01N33/6812 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/085 ,  Y02A90/26

摘要： The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a liver disease in a subject and a method of differentiating between NASH and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

公开(公告)号：EP3502703A1

公开(公告)日：2019-06-26

申请号：EP17209996.2

申请日：2017-12-22

申请人： metanomics Health GmbH

发明人： SCHULZE-PELLENGAHR, Silke ,  WAGNER-GOLBS, Antje ,  REIN, Dietrich ,  SCHATZ, Philipp ,  CHRISTIANSEN, Nicole ,  BERG, Thomas ,  HAMPE, Jochen ,  DATZ, Christian ,  STICKEL, Felix ,  LERCH, Markus

IPC分类号： G01N33/68

摘要： The present invention relates to a method for assessing non-alcoholic fatty liver disease (NAFLD) comprising determining in a sample from a subject suffering from NAFLD at least the amounts of two metabolite biomarkers, wherein said two metabolite biomarkers are: (i) at least one eicosatrienoic acid metabolite biomarker and (ii) at least one androgen metabolite biomarker and/or at least one bile acid metabolite biomarker. Further, the present invention relates to the vitro use of the two metabolite biomarkers for assessing non-alcoholic fatty liver disease (NAFLD).